Where Will AST SpaceMobile Be In 5 Years?
Ever tried to send a text from the Nevada desert…
Sell
47
ARKG Quote, Financials, Valuation and Earnings
Last price:
$23.46
Seasonality move
:
6.63%
Day range:
$22.92 - $23.84
52-week range:
$17.51 - $31.16
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
3.8M
Avg. volume:
2.7M
1-year change:
-8.96%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ARKG
ARK Genomic Revolution ETF
|
-- | -- | -- | -- | -- |
|
FXH
First Trust Health Care AlphaDEX Fund
|
-- | -- | -- | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- |
|
XBI
SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ARKG
ARK Genomic Revolution ETF
|
$23.47 | -- | -- | -- | $0.00 | 0% | -- |
|
FXH
First Trust Health Care AlphaDEX Fund
|
$101.99 | -- | -- | -- | $0.07 | 0.38% | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
$8.30 | -- | -- | -- | $0.00 | 0% | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
$63.94 | -- | -- | -- | $0.03 | 0.07% | -- |
|
XBI
SPDR S&P Biotech ETF
|
$83.60 | -- | -- | -- | $0.01 | 0.17% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ARKG
ARK Genomic Revolution ETF
|
-- | 2.130 | -- | -- |
|
FXH
First Trust Health Care AlphaDEX Fund
|
-- | 1.004 | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | 1.601 | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | 0.936 | -- | -- |
|
XBI
SPDR S&P Biotech ETF
|
-- | 0.979 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ARKG
ARK Genomic Revolution ETF
|
-- | -- | -- | -- | -- | -- |
|
FXH
First Trust Health Care AlphaDEX Fund
|
-- | -- | -- | -- | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- | -- |
|
XBI
SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- | -- |
ARK Genomic Revolution ETF vs. Competitors
-
Which has Higher Returns ARKG or FXH?
First Trust Health Care AlphaDEX Fund has a net margin of -- compared to ARK Genomic Revolution ETF's net margin of --. ARK Genomic Revolution ETF's return on equity of -- beat First Trust Health Care AlphaDEX Fund's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ARKGARK Genomic Revolution ETF-- -- -- FXHFirst Trust Health Care AlphaDEX Fund-- -- -- -
What do Analysts Say About ARKG or FXH?
ARK Genomic Revolution ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust Health Care AlphaDEX Fund has an analysts' consensus of -- which suggests that it could fall by --. Given that ARK Genomic Revolution ETF has higher upside potential than First Trust Health Care AlphaDEX Fund, analysts believe ARK Genomic Revolution ETF is more attractive than First Trust Health Care AlphaDEX Fund.
Company Buy Ratings Hold Ratings Sell Ratings ARKGARK Genomic Revolution ETF0 0 0 FXHFirst Trust Health Care AlphaDEX Fund0 0 0 -
Is ARKG or FXH More Risky?
ARK Genomic Revolution ETF has a beta of 1.728, which suggesting that the stock is 72.849% more volatile than S&P 500. In comparison First Trust Health Care AlphaDEX Fund has a beta of 0.784, suggesting its less volatile than the S&P 500 by 21.626%.
-
Which is a Better Dividend Stock ARKG or FXH?
ARK Genomic Revolution ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. First Trust Health Care AlphaDEX Fund offers a yield of 0.38% to investors and pays a quarterly dividend of $0.07 per share. ARK Genomic Revolution ETF pays -- of its earnings as a dividend. First Trust Health Care AlphaDEX Fund pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARKG or FXH?
ARK Genomic Revolution ETF quarterly revenues are --, which are smaller than First Trust Health Care AlphaDEX Fund quarterly revenues of --. ARK Genomic Revolution ETF's net income of -- is lower than First Trust Health Care AlphaDEX Fund's net income of --. Notably, ARK Genomic Revolution ETF's price-to-earnings ratio is -- while First Trust Health Care AlphaDEX Fund's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARK Genomic Revolution ETF is -- versus -- for First Trust Health Care AlphaDEX Fund. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARKGARK Genomic Revolution ETF-- -- -- -- FXHFirst Trust Health Care AlphaDEX Fund-- -- -- --
-
Which has Higher Returns ARKG or GNOM?
Global X Genomics & Biotechnology ETF has a net margin of -- compared to ARK Genomic Revolution ETF's net margin of --. ARK Genomic Revolution ETF's return on equity of -- beat Global X Genomics & Biotechnology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ARKGARK Genomic Revolution ETF-- -- -- GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -
What do Analysts Say About ARKG or GNOM?
ARK Genomic Revolution ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Genomics & Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that ARK Genomic Revolution ETF has higher upside potential than Global X Genomics & Biotechnology ETF, analysts believe ARK Genomic Revolution ETF is more attractive than Global X Genomics & Biotechnology ETF.
Company Buy Ratings Hold Ratings Sell Ratings ARKGARK Genomic Revolution ETF0 0 0 GNOMGlobal X Genomics & Biotechnology ETF0 0 0 -
Is ARKG or GNOM More Risky?
ARK Genomic Revolution ETF has a beta of 1.728, which suggesting that the stock is 72.849% more volatile than S&P 500. In comparison Global X Genomics & Biotechnology ETF has a beta of 1.189, suggesting its more volatile than the S&P 500 by 18.932%.
-
Which is a Better Dividend Stock ARKG or GNOM?
ARK Genomic Revolution ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Global X Genomics & Biotechnology ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ARK Genomic Revolution ETF pays -- of its earnings as a dividend. Global X Genomics & Biotechnology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARKG or GNOM?
ARK Genomic Revolution ETF quarterly revenues are --, which are smaller than Global X Genomics & Biotechnology ETF quarterly revenues of --. ARK Genomic Revolution ETF's net income of -- is lower than Global X Genomics & Biotechnology ETF's net income of --. Notably, ARK Genomic Revolution ETF's price-to-earnings ratio is -- while Global X Genomics & Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARK Genomic Revolution ETF is -- versus -- for Global X Genomics & Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARKGARK Genomic Revolution ETF-- -- -- -- GNOMGlobal X Genomics & Biotechnology ETF-- -- -- --
-
Which has Higher Returns ARKG or PBE?
Invesco Biotechnology & Genome ETF has a net margin of -- compared to ARK Genomic Revolution ETF's net margin of --. ARK Genomic Revolution ETF's return on equity of -- beat Invesco Biotechnology & Genome ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ARKGARK Genomic Revolution ETF-- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- -
What do Analysts Say About ARKG or PBE?
ARK Genomic Revolution ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Biotechnology & Genome ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that ARK Genomic Revolution ETF has higher upside potential than Invesco Biotechnology & Genome ETF, analysts believe ARK Genomic Revolution ETF is more attractive than Invesco Biotechnology & Genome ETF.
Company Buy Ratings Hold Ratings Sell Ratings ARKGARK Genomic Revolution ETF0 0 0 PBEInvesco Biotechnology & Genome ETF0 0 0 -
Is ARKG or PBE More Risky?
ARK Genomic Revolution ETF has a beta of 1.728, which suggesting that the stock is 72.849% more volatile than S&P 500. In comparison Invesco Biotechnology & Genome ETF has a beta of 0.809, suggesting its less volatile than the S&P 500 by 19.078%.
-
Which is a Better Dividend Stock ARKG or PBE?
ARK Genomic Revolution ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Invesco Biotechnology & Genome ETF offers a yield of 0.07% to investors and pays a quarterly dividend of $0.03 per share. ARK Genomic Revolution ETF pays -- of its earnings as a dividend. Invesco Biotechnology & Genome ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARKG or PBE?
ARK Genomic Revolution ETF quarterly revenues are --, which are smaller than Invesco Biotechnology & Genome ETF quarterly revenues of --. ARK Genomic Revolution ETF's net income of -- is lower than Invesco Biotechnology & Genome ETF's net income of --. Notably, ARK Genomic Revolution ETF's price-to-earnings ratio is -- while Invesco Biotechnology & Genome ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARK Genomic Revolution ETF is -- versus -- for Invesco Biotechnology & Genome ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARKGARK Genomic Revolution ETF-- -- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- --
-
Which has Higher Returns ARKG or XBI?
SPDR S&P Biotech ETF has a net margin of -- compared to ARK Genomic Revolution ETF's net margin of --. ARK Genomic Revolution ETF's return on equity of -- beat SPDR S&P Biotech ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ARKGARK Genomic Revolution ETF-- -- -- XBISPDR S&P Biotech ETF-- -- -- -
What do Analysts Say About ARKG or XBI?
ARK Genomic Revolution ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Biotech ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that ARK Genomic Revolution ETF has higher upside potential than SPDR S&P Biotech ETF, analysts believe ARK Genomic Revolution ETF is more attractive than SPDR S&P Biotech ETF.
Company Buy Ratings Hold Ratings Sell Ratings ARKGARK Genomic Revolution ETF0 0 0 XBISPDR S&P Biotech ETF0 0 0 -
Is ARKG or XBI More Risky?
ARK Genomic Revolution ETF has a beta of 1.728, which suggesting that the stock is 72.849% more volatile than S&P 500. In comparison SPDR S&P Biotech ETF has a beta of 0.919, suggesting its less volatile than the S&P 500 by 8.063%.
-
Which is a Better Dividend Stock ARKG or XBI?
ARK Genomic Revolution ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SPDR S&P Biotech ETF offers a yield of 0.17% to investors and pays a quarterly dividend of $0.01 per share. ARK Genomic Revolution ETF pays -- of its earnings as a dividend. SPDR S&P Biotech ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARKG or XBI?
ARK Genomic Revolution ETF quarterly revenues are --, which are smaller than SPDR S&P Biotech ETF quarterly revenues of --. ARK Genomic Revolution ETF's net income of -- is lower than SPDR S&P Biotech ETF's net income of --. Notably, ARK Genomic Revolution ETF's price-to-earnings ratio is -- while SPDR S&P Biotech ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARK Genomic Revolution ETF is -- versus -- for SPDR S&P Biotech ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARKGARK Genomic Revolution ETF-- -- -- -- XBISPDR S&P Biotech ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is TTD The Big Winner If Pharma Ads Are Banned?
Last week, Senators Bernie Sanders and Angus King introduced a…
Is Palantir Stock Overvalued?
By every traditional yardstick, including a price‑to‑sales well above 100,…
Stock Ideas
Buy
65
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 48x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Alerts
Sell
11
VEON alert for Jun 14
VEON [VEON] is down 18.57% over the past day.
Buy
74
DAVE alert for Jun 14
Dave [DAVE] is down 12.68% over the past day.
Buy
54
DAR alert for Jun 14
Darling Ingredients [DAR] is up 9.12% over the past day.
